You've done the reading. You know what a GLP-1 receptor agonist is, roughly how it works, and that it keeps coming up in conversations about insulin resistance and type 2 diabetes. So why haven't you started?
My guess: it isn't the science. It's the logistics. The cost question you can't get a straight answer to. The worry that your existing meds will collide with a new one. The quiet fear that a telehealth visit means a form, a credit card, and nobody actually looking at your labs.
Fair concerns. Let me take them one at a time.
The short version: if you have insulin resistance, prediabetes, or type 2 diabetes, you are not disqualified from GLP-1 care, but your situation does require more coordination than someone with no metabolic diagnosis. That means real labs, a real prescriber reviewing your current medications (especially insulin or sulfonylureas), and a plan that stays connected to whoever manages your diabetes. Cost is usually the biggest practical hurdle, not eligibility. And a good telehealth visit should feel like a clinical intake, not a checkout page.
Why I take this one personally
I'm the co-founder of tb2.health and, less glamorously, its patient zero. I built this thing partly because I was the guy with the creeping waistline, the family history, and a lab report I didn't fully understand.
I'm not a clinician. I want to be clear about that up front, because everything below about dosing, interactions, and monitoring is the domain of licensed prescribers, and at TB2 Health that's exactly who handles it.
What I do know cold is the hesitation phase. I sat in it for a long time. The thing that finally moved me wasn't a marketing promise. It was getting specific answers to specific worries. So that's what this article is.
"Will a virtual visit actually look at my metabolic picture?"
Here's what a competent intake should involve when you have insulin resistance or type 2 diabetes in the chart:
- Labs, not vibes. A1c or fasting glucose, a lipid panel, kidney function, liver enzymes. If you've had recent labs from your primary care or endocrinology visit, bring them. They usually count.
- A full medication list. Every prescription, including insulin, sulfonylureas, metformin, SGLT2 inhibitors, DPP-4 inhibitors, blood pressure meds, and anything over the counter.
- Personal and family history. Pancreatitis, gallbladder disease, gastroparesis, thyroid cancer history (specifically medullary thyroid carcinoma or MEN2), diabetic retinopathy status, pregnancy plans.
- A conversation about goals and what you've already tried. Not a quiz. A conversation.
- A clear answer on whether you're a candidate, including "not right now."
If an intake skips all of that, that's your signal. The American Diabetes Association's Standards of Care in Diabetes frames weight management as a core component of type 2 diabetes care, but always alongside glycemic monitoring and individualized medication review. Telehealth doesn't get an exemption from that.
At TB2 Health, the visit is with a licensed prescriber, and the answer to "am I a candidate" is sometimes no, or not yet, or "get this lab done first." I'd rather tell you that than take your money.
The interaction question most people don't ask out loud
This is the one I wish more people brought up.
If you take insulin or a sulfonylurea (glipizide, glyburide, glimepiride), adding a GLP-1 receptor agonist can increase your risk of hypoglycemia. This is on the FDA-approved labeling for these medications, and the standard clinical response is to consider reducing the dose of the insulin or secretagogue when the GLP-1 is started or titrated. The FDA's drug label database spells this out for each product.
Translation: this is not a reason to avoid care. It is a reason to avoid uncoordinated care.
Which brings up the honest disclosure I owe you. TB2 Health provides physician-supervised weight management plans. We are not a replacement for the clinician who manages your diabetes. If you're on insulin or a sulfonylurea, or you wear a CGM, the right setup is a plan that talks to your existing care, not one that ignores it. Our prescribers will ask who manages your diabetes and what your recent numbers look like, and they'll want you monitoring glucose more closely during dose changes.
Bring your glucose logs. Ask for a hypoglycemia plan in writing. Know what your low-blood-sugar symptoms feel like and what you'll do about them.
"The side effects sound rough, and my gut is already unpredictable"
Gastrointestinal effects are the most commonly reported adverse events in GLP-1 clinical trials: nausea, vomiting, diarrhea, constipation. Most are mild to moderate and cluster around dose increases. Some people tolerate it easily. Some don't. Nobody can tell you in advance which you'll be.
What complicates things if you have type 2 diabetes:
- You may already be on metformin, which has its own GI profile. Some people find the combination manageable; others need timing or formulation adjustments from their prescriber.
- Diabetic gastroparesis changes the calculus. Delayed gastric emptying plus a medication that slows gastric emptying is a conversation to have explicitly.
- Dehydration risk matters more when kidney function is already a monitoring item.
Practical things that help, from someone who has lived it:
Hydrate. Boringly, relentlessly. Electrolytes if plain water isn't cutting it.
Eat protein first and eat smaller. Even when you're not hungry, eat something. Skipping meals on a GLP-1 with diabetes medications on board is how people end up feeling awful.
Report side effects early instead of white-knuckling. Titration is adjustable. That's the entire point of supervision. A slower ramp is a legitimate clinical option, not a failure.
Cost: the hurdle that's actually a hurdle
Let's be blun. For most people with insulin resistance or type 2 diabetes, the barrier isn't medical eligibility. It's money and coverage rules.
Here's the landscape as of 2026, and I'd urge you to verify anything specific to your own plan directly, because this shifts constantly:
| Situation | What generally applies | Where to verify |
|---|---|---|
| Commercial insurance, type 2 diabetes diagnosis | GLP-1s prescribed for glycemic management are more commonly covered than those prescribed for weight alone, often with prior authorization and step therapy | Your plan's formulary and prior authorization criteria |
| Commercial insurance, prediabetes or insulin resistance without a T2D diagnosis | Coverage is far less predictable; weight-management indications are frequently excluded entirely | Your benefits summary, exclusions section |
| Medicare Part D | Statutory limits have historically restricted coverage of drugs used for weight loss; coverage tied to a type 2 diabetes indication follows normal Part D formulary rules | Medicare.gov plan finder and your plan documents |
| Medicaid | Varies significantly by state | Your state Medicaid agency |
| No coverage / cash pay | Transparent cash-pay programs exist; HSA and FSA funds are often usable for qualifying medical expenses | IRS Publication 502 and your HSA administrator |
Two things I'll say without hedging.
First, "my insurance denied it" is not the end of the road. Denials often hinge on documentation, and appeals do sometimes succeed. Ask your prescriber's office what specific criteria the denial cited.
Second, we publish our program pricing openly at tb2.health because I refuse to be the company that makes you book a call to find out what something costs. What you pay, what's included, what happens if you pause. All of it visible before you commit.
"Am I too far along for this, or not far enough?"
Both versions of this worry show up constantly.
If you have prediabetes, you might feel like you haven't earned medical intervention yet. The CDC estimates that roughly 98 million American adults have prediabetes, and about 8 in 10 don't know it. Insulin resistance is not a moral failing waiting for a verdict. It's a physiological state with a long runway, and the NIDDK is clear that it develops over years through mechanisms largely outside your control.
If you've had type 2 diabetes for fifteen years and multiple medications, you might feel like the window closed. It didn't. Metabolic care is iterative by design. Your clinician adjusting the plan is the system working, not you failing it.
And if part of what's holding you back is how you feel about your body walking into another medical conversation about weight, I understand that completely. I've been weighed, measured, and lectured. A good clinical relationship should not feel like that. If yours does, that's information about the provider.
The clinician caveat, said plainly
Nothing here is medical advice, and I'm not qualified to give it. I'm a co-founder and a patient, not a physician.
Every specific in this article, whether your insulin dose needs adjusting, whether your kidney function supports starting, whether your gastroparesis history rules it out, is a decision for a licensed clinician who has your labs and your history in front of them. That's not a liability line. It's the actual value of supervised care, and it's why our program is built around prescribers and patient care coordinators rather than an algorithm and a shopping cart.
If you already have an endocrinologist or a primary care physician managing your diabetes, keep them. Tell them what you're considering. Good care coordinates.
Where to go from here
Pick the smallest next step you'll actually take.
Pull your most recent labs. Write down your current medication list, doses included. Write down the three questions you'd want answered before you'd say yes to anything. Then take those to a clinician, ours or anyone's, and see whether the answers hold up.
The hesitation you're feeling isn't weakness. It's you wanting to make a good decision with incomplete information. That's reasonable. The fix is better information, not more willpower.
Get the information. Then decide. You can start with a medical intake at tb2.health whenever you're ready, and "not yet" is a perfectly acceptable outcome of that conversation.
Paul Moss Co-founder, tb2.health
This article is for general education and is not medical advice. GLP-1 receptor agonists are prescription medications with risks including gastrointestinal effects, pancreatitis, gallbladder disease, and a boxed warning regarding thyroid C-cell tumors in rodents. They are not appropriate for everyone. Discuss your individual situation, including all current medications, with a licensed healthcare provider.
